
    
      OBJECTIVES:

        -  Evaluate clinical and biochemical parameter response in patients with Ménétrier disease
           at high risk of developing gastric cancer treated with cetuximab.

      OUTLINE: This is a non-randomized study.

      Patients receive cetuximab IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks in
      the absence of disease progression or unacceptable toxicity.

      Patients complete a quality of life questionnaire at baseline and during week 4.

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
    
  